

**Dominant yeast and mammalian RAS mutants
that interfere with the CDC25-dependent
activation of wild-type RAS in *Saccharomyces
cerevisiae*.**

S Powers, K O'Neill and M Wigler
Mol. Cell. Biol. 1989, 9(2):390. DOI: 10.1128/MCB.9.2.390.

Updated information and services can be found at:
<http://mcb.asm.org/content/9/2/390>

CONTENT ALERTS

These include:

Receive: RSS Feeds, eTOCs, free email alerts (when new articles
cite this article), [more»](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Dominant Yeast and Mammalian *RAS* Mutants That Interfere with the *CDC25*-Dependent Activation of Wild-Type *RAS* in *Saccharomyces cerevisiae*

SCOTT POWERS,[†] KATHY O'NEILL, AND MICHAEL WIGLER*
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724

Received 8 September 1988/Accepted 24 October 1988

Two mutant alleles of *RAS2* were discovered that dominantly interfere with wild-type *RAS* function in the yeast *Saccharomyces cerevisiae*. An amino acid substitution which caused the dominant interference was an alanine for glycine at position 22 or a proline for alanine at position 25. Analogous mutations in human *H-ras* also dominantly inhibited *RAS* function when expressed in yeast cells. The inhibitory effects of the mutant *RAS2* or *H-ras* genes could be overcome by overexpression of *CDC25*, but only in the presence of wild-type *RAS*. These results suggest that these mutant *RAS* genes interfere with the normal interaction of *RAS* and *CDC25* proteins and suggest that this interaction is direct and has evolutionarily conserved features.

RAS proteins share a feature common to other guanine-nucleotide-binding proteins in that the GTP-bound form of the protein, but not the GDP-bound form, activates the target effector (1, 20). Biochemical evidence in support of this comes from studies in *Saccharomyces cerevisiae* in which *RAS2* protein has been shown to activate adenylate cyclase when bound to GTP, but not when bound to GDP (11, 15, 16), and from studies of frog oocytes, in which only the GTP-bound form of *RAS* protein induces oocyte maturation (44). It is therefore of interest to identify components that can control the guanine-nucleotide bound to *RAS* proteins and thereby control its activity. Recently, a protein has been identified which accelerates hydrolysis of GTP by mammalian *RAS* proteins (19, 44). In other guanine-nucleotide-binding protein systems, the conversion of GDP-bound to GTP-bound protein is controlled by the activity of distinct nucleotide exchange catalysts (20, 41). There is some preliminary evidence that, in *S. cerevisiae*, the *CDC25* protein may fulfill this role for *RAS1* and *RAS2* proteins (6, 10, 38).

The *CDC25* gene was originally identified by a temperature-sensitive (Ts) mutation that causes *S. cerevisiae* to arrest their progression through the cell cycle uniformly in G1 (37). This terminal arrest phenotype is exhibited by other cell cycle mutations such as *cdc35*, which is allelic to *CYR1*, the gene that encodes adenylate cyclase (3, 8, 24, 33). *CDC25* mutations significantly reduce cyclic AMP levels (6, 7, 32). Epistasis studies have suggested that the *CDC25* gene product acts upstream of *RAS* proteins in the control of adenylate cyclase (6, 31, 38). Based on the GTP requirement for adenylate cyclase activity in membranes prepared from *cdc25* mutants, yeast *RAS* proteins appear to require *CDC25* function to become bound to GTP (6).

In this report, we have utilized dominant-interfering mutants of *RAS2* and *H-ras* to further explore the relationship between *CDC25* and *RAS* proteins.

MATERIALS AND METHODS

Strains. Wild-type strains SP1 (*MAT α leu2 ura3 his3 trp1 ade8 gal2 can1*) and RS16-4C (*MAT α ura3 his3 trp1 ade2*

ade8) were used in these studies (36). The *ras1::URA3 RAS2^{Val-19}* strain PT1-6 was derived from SP1 by transformation (36). PT1-6 is the parental strain for the STS revertant series, including STS13, STS35, and STS37. The *ras2::URA3* strain KP-2 was derived from SP1 by transformation (26). RS60-3A (*MAT α RAS2^{Val-19, Ala-22} ura3 his3 ade8 trp1*) was derived from a cross between STS13 and RS16-4C. SDR-3 is a His⁺ transformant of SP1 containing plasmid p*GAL10-H-ras^{Val-12, Ala-15}* integrated at the *HIS3* locus (see below).

Cloning and assaying the activity of the dominant *RAS2*(Ts) alleles. Genomic DNA from strains STS13, STS35, and STS37 was digested to completion with *EcoRI* and *HindIII*, and DNA libraries were constructed in pUC9 from size-selected DNA. The *RAS2* locus is contained within a 3.0-kilobase-pair *EcoRI-HindIII* fragment (35). The libraries were screened with a *RAS2* probe. Positive candidates pSTS13, pSTS35, and pSTS37 were isolated from their respective libraries.

Biological activity of the cloned genes was assayed in the following manner. The 3.0-kilobase-pair *EcoRI-HindIII* fragments were cloned into the *URA3* integration vector YIp5 (2), and the resultant plasmids were digested with *Clal*, which cleaves within the *RAS2* locus (35). The linearized plasmids were used to transform strain SP1, and the Ura⁺ transformants were tested for growth at 37°C. A YIp5-based plasmid containing wild-type *RAS2* served as a negative control.

Localization of the *RAS2*(Ts) activity. *PstI* cleaves the *RAS2* coding sequence within codons 65 and 66 (35). Chimeric plasmids encoding the first 65 amino acids from the *RAS2*(Ts) alleles and the remaining 257 amino acids from *RAS2^{Val-19}* were constructed by transfer of the appropriate *EcoRI-PstI* fragments of the pSTS plasmids into vector arms provided by p*RAS2^{Val-19}*. Likewise, chimeric plasmids encoding the C-terminal 257 amino acids of the *RAS2*(Ts) alleles and the first 65 amino acids of *RAS2^{Val-19}* were constructed by transfer of the appropriate *PstI-HindIII* fragments of the pSTS plasmids into vector arms provided by p*RAS2^{Val-19}*. Biological activity was assayed as described above.

Oligonucleotide-directed mutagenesis. The *EcoRI-PstI* fragments of p*RAS2* and p*RAS2^{Val-19}* (26) were transferred

* Corresponding author.

[†] Present address: Department of Biochemistry, Robert Wood Johnson Medical School, Piscataway, NJ 08854.

into M13 vectors. Single-stranded DNA was annealed to oligonucleotides, extended, and transformed into *ung Escherichia coli* as described before (27, 45). The candidate mutants were then sequenced. Plasmids pRAS2^{Ala-22}, pRAS2^{Pro-25}, pRAS2^{Val-19, Ala-22}, and pRAS2^{Val-19, Pro-25} were constructed by transfer of the *EcoRI-PstI* fragments from the mutant pUC plasmids into vector arms provided by pRAS2. Biological activity was assayed as described above.

The oligonucleotide-derived mutants of H-*ras* were constructed in pUC vectors with *Sall-BamHI* fragments containing either H-*ras*^{Val-12} or wild-type H-*ras*, as described in reference 25. The mutant H-*ras* alleles were transferred into the *GAL10* expression vector YEP51 (4) as described previously (25). The *HIS3*⁺ integration vectors p*GAL10*-H-*ras*^{Ala-15} and p*GAL10*-H-*ras*^{Val-12, Ala-15} were constructed by transferring the *EcoRI-XbaI* fragments containing the mutant *GAL10*-H-*ras* alleles into a pBR322-based vector containing *HIS3*.

Other plasmids. YEpRAS2-1, YEpRAS2^{Val-19}, YEpCDC 25-1, and YEp*TPK1* are YEp13-based plasmids that have been described previously (6, 35, 43). pRG2 contains the 3.0-kilobase-pair *EcoRI-HindIII* fragment from pRAS2 inserted into the intermediate copy number vector pHV1 (J. Nikawa, unpublished data). pHV1 contains the polylinker from pUC18, the *HIS3* gene, and an *HpaI-HindIII* fragment from 2 μ m including the origin of replication but lacking *REP3* (5).

RESULTS

Isolation and characterization of temperature-sensitive RAS2 alleles. We have isolated several phenotypic revertants of the *ras1*⁻ *RAS2*^{Val-19} strain PT1-6, using heat shock survival after stationary phase as a selective assay (36). As reported previously, 43 heat-shock-resistant revertants have been isolated at 25°C that have the additional property of temperature-sensitive growth at 35°C (36). Eighteen of these 43 temperature-sensitive revertants appeared to be intragenic revertants for the following reason: when mated to cells with the *RAS2*^{Val-19} mutant allele, heat-shock-sensitive diploid cells were formed and when mated to wild-type cells, heat-shock-resistant diploid cells were formed. These results are consistent with the occurrence of suppressor lesions within the *RAS2*^{Val-19} gene carried by PT1-6.

Three of these 18 revertants (STS1, STS3, and STS8) were mated to wild-type cells, and the resultant diploids were sporulated and dissected. Tetrad analysis confirmed the intragenic nature of the phenotypic reversion (4:0 segregation of heat shock resistance to heat shock sensitivity in 35 complete tetrads). This analysis also indicated that the temperature-sensitive alleles segregated independently of *RAS1* but required the absence of *RAS1* (*ras1*::*URA3*) for phenotypic penetrance (31 of 70 *ras1*⁻ haploids were temperature sensitive, and 0 of 70 *RAS1*⁺ haploids were temperature sensitive). Thus, these three strains appeared to contain recessive, temperature-sensitive *ras2* alleles [*ras2*(Ts)]. Complementation tests with a mating strain constructed from one of these crosses showed that 15 of 18 of these revertants behaved as if they also contained recessive *ras2*(Ts) alleles. However, 3 of the 18 revertants behaved as if they contained dominant *RAS2*(Ts) alleles since they formed temperature-sensitive diploids when mated to strains containing wild-type *RAS* genes.

To confirm that these three particular revertants (STS13, STS35, and STS37) contained dominant temperature-sensitive *RAS2* alleles, two of them (STS13 and STS37) were

TABLE 1. Ability of overexpressed genes to suppress the temperature-sensitive defect of mutant *RAS2* strains

Strain ^a	Suppression of temperature-sensitive phenotype by high-copy plasmids ^b				
	<i>RAS1</i>	<i>RAS2</i>	<i>RAS2</i> ^{Val-19}	<i>CYR1</i>	<i>TPK1</i>
STS1	+	+	+	+	+
STS3	+	+	+	+	+
STS8	+	+	+	+	+
STS13	-	-	+	+	+
STS35	-	-	+	+	+
STS37	+	+	+	+	+

^a All STS strains were derived from PT1-6 (*ras1*⁻ *RAS2*^{Val-19}) and contained temperature-sensitive *ras2* or *RAS2* alleles as described in the text.

^b STS strains were transformed with YEp13-based vectors containing *RAS1*, *RAS2*, *RAS2*^{Val-19}, *CYR1*, or *TPK1* (see Materials and Methods). Five transformants from each group were patched onto SC-Leu plates and replica plated onto YPD plates for assessing growth at 35°C. YEp13 transformants served as a negative control.

mated to a wild-type strain and the resultant diploids were subjected to tetrad analysis. In 10 complete tetrads from each cross, the temperature-sensitive phenotype segregated 2:2 despite the presence of wild-type *RAS1*. A *RAS1*⁺ temperature-sensitive strain from the STS13 cross (RS60-12D) was mated to the *ras2*::*URA3* strain KP-2 to study linkage of the temperature-sensitive phenotype to the *RAS2* locus. The segregation pattern of Ura⁺ and Ts⁻ indicated complete linkage of the temperature-sensitive phenotype to the *RAS2* locus (no recombinants in 23 complete tetrads). We therefore concluded that STS13 contains a dominant temperature-sensitive *RAS2* allele [*RAS2*(Ts)]. Proof that the other two strains (STS35 and STS37) contain dominant *RAS2*^{ts} alleles comes from cloning experiments described in a later section. Thus, there are two classes of intragenic mutations of *RAS2*^{Val-19} that revert the *RAS2*^{Val-19} phenotype and have temperature-sensitive function: the predominant class (15 of 18), composed of typical recessive loss-of-function temperature-sensitive alleles; and the other class (3 of 18), composed of dominant *RAS2*(Ts) alleles.

To explore the nature of the dominant interference with growth, the three revertants containing dominant *RAS2*(Ts) alleles were transformed with various high-copy plasmids which overexpress genes of the *RAS*/cyclic AMP pathway. As a control, three strains containing recessive *ras2*(Ts) alleles (and *ras1*::*URA3*) were transformed with the same plasmids. Growth at 35°C was restored in all six of these mutant strains by overexpression of the adenylate cyclase gene *CYR1* (24) or by overexpression of the cyclic AMP-dependent protein kinase gene *TPK1* (43; see Table 1). Thus, downstream activation of the cyclic AMP pathway can overcome the temperature-sensitive block in cell growth imposed by both recessive *ras1*⁻ *ras2*(Ts) mutations and the dominant *RAS2*(Ts) mutations. As expected, overexpression of *RAS1* or *RAS2* restored growth at 35°C to the *ras1*⁻ *ras2*(Ts) mutant (Table 1). The temperature-sensitive defect of two of the dominant *RAS2*(Ts) mutants, however, was not overcome by overexpression of wild-type *RAS1* or *RAS2*, although the temperature-sensitive defect of STS37 was suppressed (Table 1). Even vast overexpression of wild-type *RAS2*, using the *GAL10* promoter, cannot reverse the temperature-sensitive defect of dominant *RAS2*(Ts) mutants STS13 and STS35 (data not shown). Some of the dominant *RAS2*(Ts) alleles are therefore capable of blocking *RAS* function even in the presence of a vast excess of wild-type *RAS*. Thus, it is unlikely that these dominant *RAS2*(Ts)

proteins are interfering with wild-type RAS proteins by forming ineffective multimeric RAS protein complexes, a common mechanism of inhibition found in dominant-interfering mutants (22). The effect of the RAS2(Ts) protein from STS37, however, is competitively reversed by overexpression of wild-type RAS.

Overexpression of RAS2^{Val-19} does overcome the temperature-sensitive block induced by all of the RAS2(Ts) alleles (Table 1). Furthermore, the heat-shock-sensitive phenotype induced by RAS2^{Val-19} is not influenced by the presence of RAS2(Ts) alleles (data not shown). Thus, the dominant RAS2(Ts) alleles, although they are capable of blocking the function of wild-type RAS and, in some cases, overexpressed wild-type RAS, do not interfere with the function of activated RAS2^{Val-19}. In fact, even single-copy RAS2^{Val-19} is epistatic to all of the dominant RAS2(Ts) alleles, since diploids formed between RAS2(Ts) strains and RAS2^{Val-19} strains are fully heat shock sensitive and are not temperature sensitive for growth. It seems likely, therefore, that the dominant RAS2(Ts) proteins are blocking a step required for the activation of wild-type yeast RAS proteins and that they are not blocking a step involved in the interaction of RAS proteins with their target effector.

Molecular analysis of the dominant temperature-sensitive RAS2 alleles. We cloned the RAS2(Ts) alleles from STS13, STS35, and STS37 by screening genomic libraries with a RAS2 probe (see Materials and Methods). The cloned RAS2(Ts) alleles were transferred to the yeast integration vector YIp5 and transformed into yeast strain SP1 (see Materials and Methods). All three cloned RAS2(Ts) alleles were capable of dominantly inducing temperature-sensitive growth at 37°C (data not shown).

To localize the RAS2 mutations that altered their properties, we made chimeras between the dominant RAS2(Ts) and wild-type RAS2 genes (see Materials and Methods). The temperature-sensitive lesions for all three alleles were localized to within DNA encoding the first 66 N-terminal amino acids. We sequenced the three cloned genes within this region, and in each case a single nucleotide change, resulting in a single amino acid substitution, was detected. In STS13 and STS35, a G-to-C transversion in the 22nd codon (GGT to GCT) resulted in a substitution of alanine for glycine. In STS37, a G-to-C transversion in the 25th codon (GCT to CCT) resulted in a substitution of proline for alanine. To confirm that these single amino acid substitutions caused the dominant temperature-sensitive phenotype, and to test whether these substitutions would cause a dominant temperature-sensitive phenotype if position 19 encoded glycine (wild type) instead of valine, we constructed four RAS2 genes by oligonucleotide-directed mutagenesis: RAS2^{Val-19, Ala-22}, RAS2^{Val-19, Pro-25}, RAS2^{Ala-22}, and RAS2^{Pro-25} (see Materials and Methods). All four of these genes were transferred into the yeast integration vector YIp5 and transformed into strain SP1, and all four genes induced temperature-sensitive growth (data not shown). We conclude, therefore, that the amino acid substitution observed in the RAS2(Ts) alleles of STS13 and STS35 (a glycine-to-alanine substitution at position 22) and the amino acid substitution observed in the RAS2(Ts) allele of STS37 (an alanine-to-proline substitution at position 25) are each sufficient to convert a wild-type RAS2 into a dominantly interfering gene.

Ability of CDC25 overexpression to reverse the effect of the dominant-interfering RAS2(Ts) genes. The ability of the dominant RAS2^{Val-19, Ala-22} alleles to block cell growth even in the presence of excess wild-type RAS, but not when

TABLE 2. Evidence that suppression of the temperature-sensitive phenotype of STS13 requires both overexpression of CDC25 and the presence of RAS2^a

Presence of gene on high-copy plasmids		No. of colonies with given phenotype	
RAS2	CDC25	Ts ⁺	Ts ⁻
-	-	2	145
-	+	0	54
+	-	1	343
+	+	349	11

^a Strain STS13 (*ras1*⁻ RAS2^{Val-19, Ala-22}) was transformed with both an episomal RAS2 plasmid (*HIS3*⁺) and a high-copy CDC25 plasmid (*LEU2*⁺). After plasmid segregation (see text), the temperature-sensitive phenotype of individual colonies was scored at 35°C on YPD plates, as was the presence or absence of the two plasmids.

RAS2^{Val-19} is present, is reminiscent of the growth inhibition induced by disruption of CDC25 (6, 38). We wished therefore to explore the possibility that the dominant RAS2(Ts) genes might block the activation of wild-type RAS proteins by depleting CDC25 protein. The *ras1*⁻ RAS2(Ts) mutants STS13 and STS37, and their RAS1⁺ counterparts RS60-3A and RS68-2B (see Materials and Methods), were transformed with the high-copy vector YEpCDC25-1 (6). We found that like *ras1*⁻ *ras2*(Ts) strains, the *ras1*⁻ RAS2(Ts) strains did not have their temperature-sensitive defect reversed by overexpression of CDC25. However, the temperature-sensitive defect of the RAS1⁺ RAS2(Ts) strains was overcome by overexpression of CDC25 (data not shown). It would appear, then, that CDC25 overexpression can reverse the temperature-sensitive defect induced by RAS2(Ts) alleles, but only in the presence of wild-type RAS.

To confirm this finding, the *ras1*⁻ RAS2^{Val-19, Ala-22} strain STS13 was transformed sequentially with YEpCDC25-1 and then with the episomal RAS2 vector pRG2 (see Materials and Methods). Double transformants were allowed to grow in nonselective media overnight to allow for loss of either or both of the CDC25 and RAS2 plasmids. Individual cells were allowed to grow into colonies and then replica plated to assess the segregation of three phenotypes: temperature-sensitive growth, the presence of high-copy CDC25 (*Leu*⁺), and the presence of wild-type RAS2 (*His*⁺). The results shown in Table 2 demonstrate the requirement of both overexpression of CDC25 and the presence of wild-type RAS2 to overcome the temperature-sensitive block induced by RAS2^{Val-19, Ala-22}. Thus, we confirmed that overexpression of CDC25 reverses the temperature-sensitive defect imposed by RAS2^{Val-19, Ala-22} only in the presence of wild-type RAS protein. This result suggests to us that the RAS2^{Val-19, Ala-22} proteins can deplete the cell of normal, endogenous levels of CDC25 activity.

Analogous properties of H-ras^{Val-12, Ala-15} and H-ras^{Ala-15} mutants. Wild-type mammalian H-ras can suppress the growth defects induced by disruption of CDC25 (31), whereas high expression of yeast RAS proteins does not (6, 31). This has raised the possibility that H-ras protein does not interact with CDC25 protein. We decided to reexamine this question by constructing H-ras mutants with amino acid substitutions analogous to the substitutions found in the dominant interfering RAS2(Ts) mutant genes. We used oligonucleotide site-directed mutagenesis to construct two H-ras genes: H-ras^{Ala-15} and H-ras^{Val-12, Ala-15} (see Materials and Methods). These genes were transferred into the galactose-inducible yeast expression vector YEp51 (5). We transformed the wild-type strain SP1 with YEp51 vectors

TABLE 3. Ability of overexpressed genes to override growth inhibition of H-*ras*^{Val-12, Ala-15a}

Overexpressed gene	Growth of colonies (no.) on YP + galactose	
	Ts ⁻	Ts ⁺
None	113	0
<i>RAS2</i>	55	2
<i>TPK1</i>	1	87
<i>CDC25</i>	2	120

^a Strain SDR3, which expresses H-*ras*^{Val-12, Ala-65} when induced with galactose (see text), was transformed with various high-copy plasmids, including YEp13, YEp*RAS2*, YEp*TPK1*, and YEp*CDC25-1* (see Materials and Methods). Four days later, the transformed colonies were replica plated onto either glucose- or galactose-containing plates and incubated at 37°C. The ability of the high-copy plasmids to restore growth at 37°C on galactose-containing plates was scored after 2 days.

expressing wild-type H-*ras*, H-*ras*^{Val-12}, H-*ras*^{Ala-15}, and H-*ras*^{Val-12, Ala-15} and tested the effect of galactose-induced expression on the temperature-sensitive growth properties of the transformants. The expression of neither wild-type H-*ras* nor H-*ras*^{Val-12} interfered with growth on galactose-containing medium at any temperature tested. However, expression of both H-*ras*^{Ala-15} and H-*ras*^{Val-19, Ala-15} blocked growth on galactose at all temperatures tested. The effect was more pronounced at higher temperatures (total growth inhibition at 35°C) and somewhat leaky at 23°C (thin patches formed after 4 days).

We tested whether various high-copy plasmid vectors containing genes of the RAS/cAMP pathway could reverse the effects of the mutant H-*ras* genes. Since the YEp51 vectors and our *CDC25* overexpression vectors both utilize the *LEU2* marker, we constructed *HIS3*⁺ vectors containing H-*ras*^{Ala-15} and H-*ras*^{Val-19, Ala-15} (see Materials and Methods). These integration vectors were transformed into SP1 after cleavage within the *HIS3* gene by *Xho*I to site direct integration into the *HIS3* locus. Both of these integration vectors were found to block growth in the presence of galactose, although the effect was much more temperature dependent than with the high-copy episomal vectors expressing the mutant H-*ras* genes. Strain SDR-3, which expresses H-*ras*^{Val-12, Ala-15} when induced with galactose, was transformed with high-copy vectors which overexpressed wild-type *RAS2*, the cAMP-dependent protein kinase gene *TPK1*, and *CDC25*. The effect of these high-copy plasmids is shown in Table 3. As expected, overexpression of *TPK1* reversed the temperature-sensitive defect. Overexpression of wild-type *RAS2* did not enhance cell growth (Table 3), indicating that the block of wild-type RAS function cannot be inhibited by an abundance of wild-type RAS protein. Overexpression of *CDC25* completely reverses the temperature-sensitive defect (Table 3). Thus, the H-

ras^{Val-12, Ala-15} mutant, like the dominant *RAS2*(Ts) alleles, acts to block RAS function by depleting the normal endogenous supply of *CDC25* activity. This result suggests that H-*ras* protein can interact with *CDC25* protein in a manner analogous to the interaction of *RAS2* protein with *CDC25* protein.

DISCUSSION

We have described dominant mutations of *RAS2* and H-*ras* which interfere with wild-type RAS function in *S. cerevisiae*. The evidence is clear that the mutant RAS genes interfere with the activation of normal RAS proteins, since the interference can be overcome by expression of mutationally activated *RAS2*^{Val-19}. More specifically, interfering RAS mutants appear to block *CDC25* activity, since overexpression of *CDC25* protein, which acts upstream of RAS protein and is required for its activation (6, 38), can overcome the interference if wild-type RAS protein is also present. Overexpression of *CDC25* has no apparent phenotype in an otherwise wild-type cell (6), nor does it suppress the temperature-sensitive defect of yeast cells expressing only temperature-sensitive RAS proteins. We therefore propose that interfering RAS protein forms a complex with *CDC25* protein and thereby blocks its activity.

We propose that the mechanism of interaction between *CDC25* and RAS proteins may be evolutionarily conserved, since expression of H-*ras*^{Ala-15} seems to deplete the normal supply of *CDC25* protein in *S. cerevisiae*. Moreover, Sigal and co-workers have reported that an H-*ras*^{Asn-16} mutation also induces a dominant temperature-sensitive growth arrest that likewise can be reversed by the expression of an activated *RAS2* mutant gene (40). Recently, Feig and Cooper reported similar mutations in mammalian cells (14). They found that an H-*ras*^{Asn-17} mutant inhibits proliferation of mouse NIH 3T3 cells and that the effect of H-*ras*^{Asn-17} is reversed by expression of the activated mutant H-*ras*^{Val-12} gene (14). This strongly suggests to us that a protein with the properties of the *CDC25* protein also exists in mammalian cells and is required for activation of wild type H-*ras* protein. We have not tested the H-*ras*^{Asn-17} mutant in yeast cells or the H-*ras*^{Ala-15} mutant in mammalian cells.

The amino acid substitutions occurring in the dominant *RAS2*^{ts} proteins are located in a highly conserved guanine-nucleotide-binding region (Table 4). The mutation found by Feig and Cooper is located in this region (14), as is the mutant H-*ras* described by Sigal and co-workers (40). The RAS-like gene products, such as *RHO*, *YPT*, and *SEC4*, and G proteins, such as G_sα, G_iα, and transducins, have conserved residues corresponding to residues 10 to 18 of the human H-*ras* protein and virtual identity at positions which correspond to residues 15, 16, and 17 (18, 21, 23, 28–30, 34, 39, 42). This region corresponds to a consensus nucleotide-

TABLE 4. Partial amino acid sequence of RAS and RAS-like proteins in region of interfering mutant proteins^a

Protein	Sequence	Positions	Reference(s)
H- <i>ras</i>	GLY ALA GLY GLY VAL GLY LYS SER ALA	10–18	13
<i>RAS1,2</i>	GLY GLY GLY GLY VAL GLY LYS SER ALA	17–25	35
<i>YPT1</i>	GLY ASN SER GLY VAL GLY LYS SER CYS	15–23	18, 21
<i>SEC4</i>	GLY ASP SER GLY VAL GLY LYS SER CYS	27–35	39
Transducin	GLY ALA GLY GLY SER GLY LYS SER THR	40–48	28, 34

^a The region of H-*ras* and other related proteins where the mutations of the dominant-interfering genes are localized includes a highly conserved GXXXXGK sequence (in boldface) found in virtually all guanine-nucleotide-binding proteins (12). Arrows indicate positions where amino acid substitutions within H-*ras* or *RAS2* proteins lead to proteins with interfering properties.




FIG. 1. Model for RAS and CDC25 protein interactions. In step 1, RAS complexed to GDP binds to CDC25 protein. In step 2, CDC25 stabilizes the nucleotide-free state of RAS, and GDP dissociates. In step 3, GTP binds to RAS. This terminates the interaction, and in step 4 CDC25 protein is free to interact with another RAS protein. According to this model, the dominant interfering RAS proteins cannot proceed through steps 3 and 4 and instead remain bound to CDC25, preventing it from interacting with wild-type RAS protein.

binding sequence, GXXXXGK (Table 4). The interfering mutant H-ras proteins of Feig and Cooper and of Sigal and co-workers both exhibit altered affinity for guanine nucleotides (14, 40). This suggests that alterations in guanine-nucleotide-binding properties underlie the ability of the mutant RAS proteins to deplete CDC25 activity in cells.

The results presented in this report lead us to propose a simple model for the inhibition of wild-type RAS function by the dominant *RAS2(Ts)* mutants (Fig. 1). We propose that RAS and CDC25 proteins normally undergo a transient, direct interaction, similar to the transient interaction of receptors with G proteins (20, 41). In this model, CDC25 proteins interact with the GDP-bound form of RAS proteins and, by virtue of stabilizing the transitional state of nucleotide-free RAS protein, catalyze nucleotide exchange. This mechanism of catalysis (stabilization of the nucleotide-free transitional state) has been proposed by Stryer for the activation of transducin by photorhodopsin (41). When GTP binds to RAS protein, the interaction is terminated and CDC25 protein is free to interact with another RAS protein. We propose that the dominant-interfering RAS proteins remain bound to CDC25 protein, because either a severely impaired ability to bind guanine nucleotides or a selective inability to bind GTP results in a failure to terminate the interaction with CDC25 protein. The net result of the interaction between CDC25 and interfering RAS proteins is to prevent CDC25 protein from interacting with wild-type RAS proteins. This causes a *cdc25*-like state, consistent with the genetic experiments we described.

We envision that mutants in other RAS-like genes, similar to the dominant-interfering mutants we have described, may aid in identification of their respective CDC25-like gene product. The ability of overexpression of CDC25 to suppress

the dominant *RAS2(Ts)* mutations only in the presence of wild-type RAS forms the basis for a highly selective genetic screen. We also envision that mutant RAS genes encoding proteins blocked in other steps of the RAS protein cycle can be identified and utilized for the study of other proteins with which RAS proteins interact. In support of this, an H-ras mutant capable of interfering with the function of *RAS2^{Val-19}* has been isolated and characterized recently (T. Michaeli, et al., unpublished data). The existence of interfering mutants in signal transduction pathways may be quite general (22). For example, we have found dominant-interfering forms of adenylate cyclase in yeast cells which appear to block RAS function (J. Field et al., unpublished data). Analogous mutants may exist for the targets of H-ras proteins in mammalian cells. We have seen that mutant oncogene products may interfere with cell growth. As a further generalization, we may be able to generate interfering mutants of "recessive" oncogenes, such as the retinoblastoma gene (9, 17), which thereby become dominant oncogenes.

ACKNOWLEDGMENTS

We thank D. Broek, K. Ferguson, and T. Toda for helpful insights and P. Bird for preparing the manuscript.

This work was supported by grants from the Public Health Service National Institutes of Health, American Business Foundation for Cancer Research, American Cancer Society, and Pfizer Biomedical Research Award. M.W. is an American Cancer Society Research Professor.

LITERATURE CITED

1. Barbacid, M. 1987. *ras* genes. *Annu. Rev. Biochem.* **56**:779-828.
2. Botstein, D., and R. W. Davis. 1982. Principles and practice of recombinant DNA research with yeast, p. 607-636. *In* J. N. Strathern, E. W. Jones, and J. R. Broach (ed.), *The molecular biology of the yeast Saccharomyces: metabolism and gene expression*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
3. Boutelet, F., A. Petitjean, and F. Hilger. 1985. Yeast CDC35 mutants are defective in adenylate cyclase and are allelic with CYR1 mutants while CAS1, a new gene, is involved in the regulation of adenylate cyclase. *EMBO J.* **4**:2635-2642.
4. Broach, J., Y. Li, L. Wu, and M. Jayaram. 1983. Vectors for high-level inducible expression of cloned genes in yeast, p. 83-177. *In* M. Inouye (ed.), *Experimental manipulation of gene expression*. Academic Press, Inc., New York.
5. Broach, J. R., J. N. Strathern, and J. B. Hicks. 1979. Transformation in yeast: development of a hybrid cloning vector and isolation of the *CAN1* gene. *Gene* **8**:121-133.
6. Broek, D., T. Toda, T. Michaeli, L. Levin, C. Birchmeier, M. Zoller, S. Powers, and M. Wigler. 1987. The *S. cerevisiae* CDC25 gene product regulates the RAS/adenylate cyclase pathway. *Cell* **48**:789-799.
7. Camonis, J. H., M. Kalekine, G. Bernard, H. Garreau, E. Boy-Marcotte, and M. Jacquet. 1986. Characterization, cloning and sequence analysis of the CDC25 gene which controls the cyclic AMP level of *Saccharomyces cerevisiae*. *EMBO J.* **5**:375-380.
8. Caspersen, G. F., N. Walker, and H. R. Bourne. 1985. Isolation of the gene encoding adenylate cyclase in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA* **82**:5060-5063.
9. Cavenee, W. K., T. P. Dryja, R. A. Phillips, W. F. Benedict, R. Godbout, B. L. Gallie, A. L. Murphree, L. C. Strong, and R. L. White. 1983. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature (London)* **305**:779-784.
10. Daniel, J., J. M. Becker, E. Enari, and A. Levitzki. 1987. The activation of adenylate cyclase by guanyl nucleotide in *Saccharomyces cerevisiae* is controlled by the CDC25 start gene product. *Mol. Cell. Biol.* **7**:3857-3861.
11. DeVendittis, E., R. Zahn, and O. Fasano. 1986. Regeneration of

- the GTP-bound from the GDP-bound form of human and yeast ras proteins by nucleotide exchange. Stimulatory effect of organic and inorganic polyphosphates. *Eur. J. Biochem.* **161**: 473-478.
12. Dever, T. E., M. J. Glynias, and W. C. Merrick. 1987. GTP-binding domain: three consensus sequence elements with distinct spacing. *Proc. Natl. Acad. Sci. USA* **84**:1814-1818.
 13. Fasano, O., E. Taparowsky, J. Fiddes, M. Wigler, and M. Goldfarb. 1983. Sequence and structure of the coding regions of the human *H-ras-1* gene from T24 bladder carcinoma cells. *J. Mol. Appl. Genet.* **2**:173-180.
 14. Feig, L. A., and G. M. Cooper. 1988. Inhibition of NIH 3T3 cell proliferation by a mutant *ras* protein with preferential affinity for GDP. *Mol. Cell. Biol.* **8**:3235-3243.
 15. Field, J., D. Broek, T. Kataoka, and M. Wigler. 1987. Guanine nucleotide activation of, and competition between, RAS proteins from *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **7**:2128-2133.
 16. Field, J., J. Nikawa, D. Broek, B. MacDonald, L. Rodgers, I. A. Wilson, R. A. Lerner, and M. Wigler. 1988. Purification of a RAS-responsive adenylyl cyclase complex from *Saccharomyces cerevisiae* by use of an epitope addition method. *Mol. Cell. Biol.* **8**:2159-2165.
 17. Friend, S. H., R. Bernard, S. Rogelj, R. A. Weinberg, J. M. Rapaport, D. M. Albert, and T. P. Dryja. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature (London)* **323**:643-646.
 18. Gallwitz, D., C. Donath, and C. Sander. 1983. A yeast gene encoding a protein homologous to human *c-has/bas* proto-oncogene product. *Nature (London)* **306**:704-707.
 19. Gibbs, J. B., M. D. Schaber, W. J. Allard, I. S. Sigal, and E. M. Scolnick. 1988. Purification of ras GTPase activating protein from bovine brain. *Proc. Natl. Acad. Sci. USA* **85**:5026-5030.
 20. Gilman, A. G. 1987. G proteins, transducers of receptor-generated signals. *Annu. Rev. Biochem.* **56**:615-650.
 21. Haubruck, H., C. Disela, P. Wagner, and D. Gallwitz. 1987. The *ras*-related *ypt* protein is an ubiquitous eukaryotic protein: isolation and sequence analysis of mouse cDNA clones highly homologous to the yeast *YPT1* gene. *EMBO J.* **6**:4049-4053.
 22. Herskowitz, I. 1987. Functional inactivation of genes by dominant negative mutations. *Nature (London)* **329**:219-222.
 23. Itoh, H., T. Kozasa, S. Nagata, S. Nakamura, T. Katada, M. Ui, S. Iwai, E. Ohtsuka, H. Kawasaki, K. Suzuki, and Y. Kaziro. 1986. Molecular cloning and sequence determination of cDNAs for α subunits of the guanine nucleotide-binding proteins G_s , G_i , and G_o from rat brain. *Proc. Natl. Acad. Sci. USA* **83**:3776-3780.
 24. Kataoka, T., D. Broek, and M. Wigler. 1985. DNA sequence and characterization of the *S. cerevisiae* gene encoding adenylyl cyclase. *Cell* **43**:493-505.
 25. Kataoka, T., S. Powers, S. Cameron, O. Fasano, M. Goldfarb, H. Broach, and M. Wigler. 1985. Functional homology of mammalian and yeast RAS genes. *Cell* **40**:19-26.
 26. Kataoka, T., S. Powers, C. McGill, O. Fasano, J. Strathern, J. Broach, and M. Wigler. 1984. Genetic analysis of yeast *RAS1* and *RAS2* genes. *Cell* **37**:437-445.
 27. Kunkel, T. 1985. Rapid and effective site-specific mutagenesis without phenotypic selection. *Proc. Natl. Acad. Sci. USA* **82**:488-492.
 28. Lochrie, M. A., J. B. Hurley, and M. I. Simon. 1985. Sequence of the alpha subunit of photoreceptor G protein: homologies between transducin, *ras* and elongation factors. *Science* **228**: 96-99.
 29. Madaule, P., and R. Axel. 1985. A novel *ras*-related gene family. *Cell* **41**:31-40.
 30. Madaule, P., R. Axel, and A. M. Myers. 1987. Characterization of two members of the *rho* gene family from the yeast *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA* **84**:779-783.
 31. Marshall, M. S., J. B. Gibbs, E. M. Scolnick, and I. S. Sigal. 1987. Regulatory function of the *Saccharomyces cerevisiae* RAS C-terminus. *Mol. Cell Biol.* **7**:2309-2315.
 32. Martegani, E., M. Baroni, and M. Wanoni. 1986. Interaction of cAMP with the *CDC25*-mediated step in the cell cycle of *Saccharomyces cerevisiae*. *EMBO J.* **5**:375-380.
 33. Matsumoto, K., I. Uno, Y. Oshima, and T. Ishikawa. 1982. Isolation and characterization of yeast mutants deficient in adenylyl cyclase and cAMP-dependent protein kinase. *Proc. Natl. Acad. Sci. USA* **79**:2355-2359.
 34. Medynski, D. C., K. Sullivan, D. Smith, C. Van Dop, F. H. Chang, B. K. K. Fung, P. H. Seeburg, and H. R. Bourne. 1985. Amino acid sequence of the α subunit of transducin deduced from the cDNA sequence. *Proc. Natl. Acad. Sci. USA* **82**: 4311-4315.
 35. Powers, S., T. Kataoka, O. Fasano, M. Goldfarb, J. Strathern, J. Broach, and M. Wigler. 1984. Genes in *S. cerevisiae* encoding proteins with domains homologous to the mammalian *ras* proteins. *Cell* **36**:607-612.
 36. Powers, S., S. Michaelis, D. Broek, S. S. Anna-A., J. Field, I. Herskowitz, and M. Wigler. 1986. *RAM*, a gene of yeast required for a functional modification of RAS proteins and mating pheromone α -factor. *Cell* **47**:413-422.
 37. Pringle, J. R., and L. H. Hartwell. 1981. The *Saccharomyces cerevisiae* cell cycle, p. 97-142. In J. N. Strathern, E. W. Jones, and J. R. Broach (ed.), *The molecular biology of the yeast Saccharomyces: life cycle and inheritance*. (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
 38. Robinson, L. C., J. B. Gibbs, M. S. Marshall, I. S. Sigal, and K. Tatchell. 1987. *CDC25*: a component of the RAS-adenylyl cyclase pathway in *Saccharomyces cerevisiae*. *Science* **235**: 1218-1221.
 39. Salminen, A., and P. J. Novick. 1987. A *ras*-like protein is required for a post-golgi event in yeast secretion. *Cell* **49**: 527-538.
 40. Sigal, I. S., J. B. Gibbs, J. S. D'Alonzo, G. L. Temeles, B. S. Wolanski, S. H. Socher, and E. M. Scolnick. 1986. Mutant *ras*-encoded proteins with altered nucleotide binding exert dominant biological effects. *Proc. Natl. Acad. Sci. USA* **83**:952-956.
 41. Stryer, L. 1986. Cyclic GMP cascade of vision. *Annu. Rev. Neurosci.* **9**:87-119.
 42. Sullivan, K. A., Y.-C. Liao, A. Alborzi, B. Beiderman, F.-H. Chang, S. B. Masters, A. D. Levinson, and H. R. Bourne. 1986. Inhibitory and stimulatory G proteins of adenylyl cyclase: cDNA and amino acid sequences of the α chains. *Proc. Natl. Acad. Sci. USA* **83**:6687-6691.
 43. Toda, T., S. Cameron, P. Sass, M. Zoller, and M. Wigler. 1987. Three different genes in *S. cerevisiae* encode the catalytic subunits of the cAMP-dependent protein kinase. *Cell* **50**:277-287.
 44. Trahey, M., and F. McCormick. 1987. A cytoplasmic protein stimulates normal N-*ras* p21 GTPase, but does not affect oncogenic mutants. *Science* **238**:542-545.
 45. Zoller, M. J., and M. Smith. 1983. Oligonucleotide-directed mutagenesis of DNA fragments cloned in M13 vectors. *Methods Enzymol.* **100**:468-500.